Zinforo
ceftaroline fosamil
Table of contents
Overview
Zinforo is an antibiotic. It is used to treat adults and children (including newborn babies) who have:
- complicated infections of the skin and soft tissue (tissue below the skin). ‘Complicated’ means that the infection is difficult to treat;
- community-acquired pneumonia (an infection of the lungs that is caught outside of hospital).
Prescribers should consider official guidance on the appropriate use of antibiotics.
Zinforo contains the active substance ceftaroline fosamil.
-
List item
Zinforo : EPAR - Medicine overview (PDF/83.16 KB)
First published: 18/09/2012
Last updated: 17/10/2019
EMA/437479/2012 -
-
List item
Zinforo : EPAR - Risk-management-plan summary (PDF/270.13 KB)
First published: 27/03/2018
Last updated: 17/10/2019
Authorisation details
Product details | |
---|---|
Name |
Zinforo
|
Agency product number |
EMEA/H/C/002252
|
Active substance |
Ceftaroline fosamil
|
International non-proprietary name (INN) or common name |
ceftaroline fosamil
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
J01DI02
|
Publication details | |
---|---|
Marketing-authorisation holder |
Pfizer Ireland Pharmaceuticals
|
Revision |
26
|
Date of issue of marketing authorisation valid throughout the European Union |
22/08/2012
|
Contact address |
Operations Services Group
Ringaskiddy County Cork Ireland |
Product information
01/06/2021 Zinforo - EMEA/H/C/002252 - IB/0060
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antibacterials for systemic use
Therapeutic indication
Zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults:
- Complicated skin and soft tissue infections (cSSTI)
- Community-acquired pneumonia (CAP)
Consideration should be given to official guidance on the appropriate use of antibacterial agents.